.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Covington
AstraZeneca
Johnson and Johnson
Chubb
Dow
Fuji
QuintilesIMS
Federal Trade Commission
McKesson

Generated: September 22, 2017

DrugPatentWatch Database Preview

XOFIGO Drug Profile

« Back to Dashboard

Which patents cover Xofigo, and what generic Xofigo alternatives are available?

Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-one countries.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for Tradename: XOFIGO

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list14
Drug Prices:see details
DailyMed Link:XOFIGO at DailyMed

Pharmacology for Tradename: XOFIGO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XOFIGO

Country Document Number Estimated Expiration
Germany69932183► Subscribe
New Zealand513135► Subscribe
Canada2358498► Subscribe
Brazil9916768► Subscribe
Eurasian Patent Organization003496► Subscribe
Hong Kong1090750► Subscribe
Japan2010168397► Subscribe
Turkey200201440► Subscribe
Japan5433490► Subscribe
European Patent Office1140212► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XOFIGO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00027Denmark► SubscribePRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
00666Netherlands► SubscribePRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113
1140212/01Switzerland► SubscribePRODUCT NAME: RADIUM RA-223; REGISTRATION NO/DATE: SWISSMEDIC 62732 29.08.2014
425Luxembourg► SubscribePRODUCT NAME: DICHLORURE DE RADOIM RA 2232 ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(XOFIGO)
2014000052Germany► SubscribePRODUCT NAME: RADIUM-223-SALZ, INSBESONDERE RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
/2014Austria► SubscribePRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
2014 00027Denmark► SubscribePRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
90034-4Sweden► SubscribePRODUCT NAME: RADIUM-223; REG. NO/DATE: EU/1/13/873 20131113
C0038France► SubscribePRODUCT NAME: RADIUM 223 AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER LE DICHLORURE DE RADIUM 223; REGISTRATION NO/DATE: EU/1/13/873 20131113
14/033Ireland► SubscribePRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
AstraZeneca
QuintilesIMS
Dow
Teva
Johnson and Johnson
Fuji
Argus Health
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot